Citations

Clear

1413 citation(s) found for "To, Christina".

Show Me the “Mino:” In Vitro Efficacy of Minocycline on Clinical Gram-Negative Bacterial Isolates
Streck, Nicholas , Saleh, O. Abu, Crowley, Patrick D , Mira, Portia , Challener, Douglas W. , Abu Saleh, Omar , Crowley, Patrick D., Ranganath, Nischal , Rivera, Christina G. , AbuSaleh, Omar

Mayo Clinic

Microbial Drug Resistance | March 31, 2026 | Volume: 32 | Issue: 4 | Pages: 128-134

10.1177/10766294261424485 | PMID 41677880 Get It

Background: There are limited oral treatment options available for resistant Gram-negative bacterial (GNB) infections. Minocycline, a second-generation tetracycline antibiotic, offers good bioavailability and broad-spectrum coverage that may be an option for GNB infections. Methods: We conducted a retrospective review of minocycline susceptibility testing performed on GNB isolates at the Mayo Clinic reference lab between 2013 and 2022. Minocycline susceptibility was evaluated with a focus on difficult-to-treat organisms and relevant anatomic source. Organisms included resistant isolates of Escherichia coli and Klebsiella pneumoniae ; high-risk ampC-derepressors, including Citrobacter freundii, Enterobacter cloacae, and K. aerogenes; and clinically challenging non-Enterobacterales, Acinetobacter species, Achromobacter species, and Stenotrophomonas maltophilia . Results: Of 217,206 GNB isolates, 18,148 Enterobacterales (EB) and 8,190 non- Enterobacter isolates were tested for minocycline susceptibility. Of these, 80% of all EB and 92% of non-EB isolates were susceptible. Among E. coli isolates with ceftriaxone, ciprofloxacin, meropenem, or multidrug resistance, minocycline susceptibility was 78%, 76%, 70%, and 70.9%, respectively. Among the K. pneumoniae isolates with ceftriaxone, ciprofloxacin, meropenem, or multidrug resistance, minocycline susceptibility was 46%, 38%, 37%, and 39.3%, respectively. 85% of C. freundii , 81% of E. cloacae, and 85% of K. aerogenes isolates were susceptible to Minocycline. 83.5% of Achromobacter species isolates, 66% of Acinetobacter species isolates, and 99.1% of S. maltophilia isolates were susceptible. Conclusions: Our study reports the largest collection of minocycline susceptibility findings in GNB. Minocycline showed in vitro activity against many difficult-to-treat GNB isolates, including ceftriaxone- and multidrug-resistant E. coli and some K. pneumoniae isolates, common Amp-C-producing species, and non-fermenting GNB, including Stenotrophomonas , Acinetobacter , and Achromobacter .
Key Insights From the International ICU Diary Conference 2025
Nydahl, Peter, Ewens, Bev, Debue, Anne‐Sophie , Fiorilla, Xavier, Gabriel, Kristin, Galazzi, Alessandro , Gallie, Louise , Groth, Nikolas, Hickey, Carly, Hudson, Mark, Lynch, Fiona , Maxwell, Nicola G , Mol, Margo van, Rose, Louise, Tantam, Kate , Karnatovskaia, Lioudmila V. , Jones, Christina, Nydahl, Peter , van Mol, Margo , Tantam, Kate , Nydahl, Peter , Ewens, Beverley , Debue, Anne-Sophie , Galazzi, Alessandro , Renner, Caroline I. E. , Rose, Louise , Jones, Christina

Mayo Clinic

Nursing in Critical Care | March 31, 2026 | Volume: 31 | Issue: 3 | Pages: No page available

10.1111/nicc.70430 | PMID 41913061 Get It

ABSTRACT We report on the 2025 International ICU Diary Conference that provided a comprehensive update on current knowledge, innovations and global practices related to ICU diaries. Held in a 6‐week online format, the event featured 23 speakers and was attended by mean 69.7 (SD 20.5) participants per session. Topics included development of ICU diaries, use in special settings, digital diaries, survivors' and families' experiences, Post‐Intensive‐Care Syndrome and follow‐up and implementation projects. Highlights were innovative solutions for digital diaries and the report of persons with lived and living experiences with diaries, changing the focus on humanising critical care. Relevance for Practice ICU diaries support patient‐ and family‐centred care and should be implemented more widely across healthcare systems. Their successful adoption requires contextual adaptation and policy support, with future development likely to be shaped by the increasing use of digital ICU diaries.
Differential effects of α7nAChR activation in a murine model of asthma
Borkar, Niyati A. , Lee, Kenge K., Thompson, Michael A, Bartman, Colleen M. , Nesbitt, Lisa, Hamrick, Samantha K. , Fang, Yun Hua, Prakash, Y. S. , Pabelick, Christina M, Pabelick, Christina M. , Nesbitt, Lisa L, Prakash, Y S , Pabelick, Christina M , Bartman, Colleen M , Thompson, Michael A.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | March 30, 2026 | Volume: 330 | Issue: 5 | Pages: L539-L556

10.1152/ajplung.00119.2025 | PMID 41910047 Get It

The studies demonstrate the differential effects of the nicotinic acetylcholine receptors (nAChRs) regulating airway hyperreactivity (AHR) and remodeling in a mixed allergen model of asthma. We compared wild-type (WT) versus global α7nAChR knockout (Glα7KO) versus smooth muscle-specific α7nAChR KO (smα7KO) mice. We found that smα7KO improved lung function and AHR in mice challenged with MA and in the presence of nicotine, whereas MA-challenged Glα7KO in the presence of nicotine showed worsened AHR.
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
Besse, Benjamin, Subbiah, Vivek, Curigliano, G., Bowles, Daniel W. , Doebele, Robert C. , Mansfield, Aaron S. , Baik, Christina S. , Lopes, Gilberto , Paz-Ares, Luis , Taylor, Matthew H. , Tan, Daniel S.W., Alonso, G. , Gadgeel, Shirish M., Kalemkerian, Gregory P. , Ou, S.-H.I., Wekken, Anthonie J. van der , Becerra, Carlos R., Evangelist, Makenzi Colleen, Griesinger, Frank, Lou, Yanyan , Mazières, Julien, Melear, Jason M., Narang, Mohit , Saxena, Ashish, Thomas, Michael, Thomassen, Amber , Lee, Dae Ho, Kim, Dong-Wan, Gainor, Justin F., Subbiah, Vivek , Besse, Benjamin , Besse, Benjamin , Subbiah, Vivek , Curigliano, Giuseppe , Tan, Daniel S W , Gadgeel, Shirish , Ou, Sai-Hong I , van der Wekken, Anthonie J , Liu, Stephen V , Lou, Yanyan , Mazières, Julien , Melear, Jason M , Narang, Mohit , Thomas, Michael , Lee, Dae Ho , Kim, Dong-Wan , Gainor, Justin F , Mansfield, Aaron S , Bowles, Daniel W , Curigliano, Giuseppe , Paz‐Ares, Luis , Gadgeel, Shirish M. , Griesinger, Frank , Liu, Stephen V. , Saxena, Ashish , Thomas, Michael , Wang, Sophia Y. , Kim, Dong‐Wan , Gainor, Justin F. , Taylor, Matthew H.

Mayo Clinic

Journal of Clinical Oncology | March 26, 2026 | Volume: 44 | Issue: 13 | Pages: 1190-1197

10.1200/jco-25-01489 | PMID 41886723 Get It

RET fusions appear in 1%-2% of non–small cell lung cancers (NSCLCs). The results from the ARROW study (ClinicalTrials.gov identifier: NCT03037385 ) supported US Food and Drug Administration approval of pralsetinib, an oral selective RET inhibitor, for metastatic RET -altered NSCLC and RET fusion–positive thyroid cancers. ARROW was a phase I/II open-label study of pralsetinib 400 mg once daily in RET fusion–positive NSCLCs. Coprimary end points were overall response rate (ORR) and safety. Key secondary end points included duration of response, progression-free survival, and overall survival (OS). At data lock (May 20, 2024), 281 patients initiated pralsetinib (median treatment duration, 15.0 months). ORR (measurable disease patients; n = 259) was 78% (95% CI, 69 to 86) for treatment-naïve patients and 63% (95% CI, 54 to 71) for prior platinum-based chemotherapy patients. Median OS was 44.3 months (95% CI, 30.9 to 53.1), 50.1 months (95% CI, 28.3 to not reached) in treatment-naïve patients, and 39.7 months (95% CI, 27.8 to 53.2) in prior platinum patients. Common grade ≥3 treatment-related adverse events were anemia (21%), hypertension (15%), and decreased neutrophils (13%). Three treatment-related deaths occurred (pneumonia, n = 2; interstitial lung disease and rhabdomyolysis, n = 1 each). Safety was consistent with previous ARROW reports; no hypersensitivity was reported in patients receiving prior immunotherapies. Pralsetinib produced robust, durable responses with manageable safety in treatment-naïve and previously treated patients with RET fusion–positive NSCLCs, confirming previous findings with longer follow-up.
Circulating Nucleosomes are Elevated in Trauma Patients with Venous Thromboembolism: A Prospective Case-Cohort Study
Thompson, Riley J., Spears, Grant M. , Bailey, Kent R., Kelly, Theresa K., Wheeler, Christina, Dong, Jing-Fei, Kozar, Rosemary A. , Park, Myung S., Navarro, Sergio M. , Bailey, Kent R. , Kelly, Theresa Kathleen , Chen, Dong

Mayo Clinic

Shock | March 26, 2026 | Volume: 66 | Issue: 3 | Pages: 666-675

10.1097/shk.0000000000002807 | PMID 41886536 Get It

Objective: The identification of reliable biomarkers in trauma patients (pts) remains a clinical challenge. Nucleosomes, which are DNA wrapped around histone protein cores, have been used as reliable markers for quantification in sepsis, acute respiratory distress syndrome, and lymphoma. We hypothesized that: 1) levels of circulating nucleosomes quantified after traumatic injury, specifically histone H3.1 and its citrullinated R8 posttranslation modification (H3R8 Cit), would be increased after trauma and 2) that levels of circulating nucleosomes would be further, increased in pts who went on to develop venous thromboembolism (VTE), as these nucleosomes may be clot-enhancing mediators. Methods: Trauma pts presenting to a Level I trauma center were evaluated for inclusion in a prospective case-cohort study, and citrated blood samples were collected within 12 hours of injury. Pts were followed for up to 90 days and VTE occurrence was confirmed via autopsy or imaging. Pts who developed incident, symptomatic VTE, and those who did not develop VTE were selected at a 1:3 ratio. The effect of trauma was assessed by comparison with healthy volunteer samples. Circulating nucleosomes were quantified using Nu.Q H3.1 and Nu.Q H3R8 Cit assays. Data are presented as median [interquartile range] or n (%), with Wilcoxon Rank-Sum or chi-squared test performed between trauma pts who developed symptomatic VTE versus those who did not, with a P value < 0.05 as statistically significant. Results: A total of 639 trauma pts were analyzed [51 years (33, 65), 71.0% male, 94.1% blunt, injury severity scores 17 (9, 27)]. Both H3.1 [359.7 (58.4, 1769.3) vs. 21.5 (15.3, 26.6) ng/mL, P < 0.001] and H3R8 Cit levels [209.4 (45.4, 665.5) vs. 22.3 (16.2, 28.9) ng/mL, P < 0.001] were greater in trauma pts than in 10 healthy volunteers. The 160 pts with VTE were then compared with 479 without VTE. VTE pts had a median time to VTE of 8.5 days, with 91 developing symptomatic deep venous thrombosis, 48 with pulmonary embolism, and 21 with both deep venous thrombosis and pulmonary embolism. No significant differences were found in age, sex, or mechanism between pts with or without VTE. However, VTE pts had higher injury severity scores [24 (14, 34), 14 (9, 24), P < 0.001] and body mass index [29.1 (24.3, 34.2), 27.6 (24.2, 32.0) kg/m 2 , P = 0.037]. A greater percentage of VTE pts underwent surgery requiring general anesthesia (53.1%, 34.0%, P < 0.001) and received blood transfusions within 24 hours of injury (51.9%, 24.0%, P < 0.001). H3.1 levels were significantly greater in trauma pts who developed VTE compared with those who did not [828.4 (112.0, 3186.5), vs. 276.7 (50.3, 1237.0) ng/mL, P < 0.001], as were H3R8 Cit levels [350.4 (77.4, 729.5), vs. 189.2 (40.8, 632.6) ng/mL, P = 0.005]. No differences in levels of H3.1 and H3R8 Cit were found between early (diagnosed day 0–7 after injury) and late (diagnosed > day 7) VTE. Conclusions: Levels of the H3.1 and H3R8 Cit nucleosomes are elevated early after traumatic injury, especially in those who developed VTE. These findings underscore the importance of understanding the pathophysiology of nucleosomes in inducing VTE and their role as biomarkers
Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma
Jamal, Fares , Sahwan, Oudai , Abidoye, Seyi, Alsulaiman, Abdullah, Sheashaa, Hesham, Ahn, Daniel H. , Wu, Christina, Borad, Mitesh, Zhu, Mojun, Jones, Jeremy, Jin, Zhaohui, Majeed, Umair , Bekaii-Saab, Tanios, Starr, Jason S., Yoon, Harry H. , Borad, Mitesh J. , Jones, Jeremy , Wu, Christina , Abidoye, Oluseyi , Alsulaiman, Abdullah , Abidoye, Oluseyi , Alsulaiman, Abdullah A , Sheashaa, Hesham , Wu, Christina , Borad, Mitesh J , Jones, Jeremy C , Halfdanarson, Thorvardur R , Jin, Zhaohui , Babiker, Hani , Majeed, Umair , Bekaii-Saab, Tanios S , Starr, Jason S , Yoon, Harry H , Sonbol, Mohamad B , Sahwan, Oudai , Jamal, Fares , Zhu, Mojun , Hálfdánarson, Þorvarður R. , Jin, Zhaohui , Babiker, Hani M. , Bekaii‐Saab, Tanios , Starr, Jason S. , Sonbol, Mohamad Bassam

Mayo Clinic

JCO Precision Oncology | March 25, 2026 | Volume: 10 | Issue: 3 | Pages: No page available

10.1200/po-25-01194 | PMID 41881066 Get It

PURPOSE Gastroesophageal carcinoma (GEC) is increasingly managed using biomarker-guided therapies. Although both tissue DNA (tDNA) and circulating tumor DNA (ctDNA) testing are used clinically, the concordance of genomic alterations between primary tumors, metastatic sites, and liquid biopsy remains incompletely understood. METHODS We retrospectively analyzed 345 patients with GEC who underwent ctDNA testing at Mayo Clinic. tDNA next-generation sequencing and immunohistochemistry (IHC) for human epidermal growth factor receptor 2 (HER2)/erb-b2 receptor tyrosine kinase 2 ( ERBB2 ) and mismatch repair (MMR) were collected. Concordance was evaluated between ctDNA and tDNA, ctDNA and IHC, and across all three modalities, using 60-day and 30-day intervals. RESULTS Among 345 patients with ctDNA testing, 186 had tDNA testing, and 310 underwent IHC. ctDNA testing showed a shorter turnaround time than tDNA (median 6 v 13 days). The most frequent alteration in ctDNA, primary tDNA, and metastatic tDNA was TP53. Concordance between ctDNA and primary tDNA was ≥78.8% for key genes; between ctDNA and metastatic tDNA, it was ≥84.8%. IHC-ctDNA concordance was higher in metastatic tumors, with 91.1% for HER2/ ERBB2 and 97.7% for mismatch repair (MMR)/microsatellite instability (MSI) compared with 81.1% and 95.8%, respectively, in primary tumors. Triplet concordance for MSI/MMR was 97.6% in primary tumors and 100% in metastatic tumors, while ERBB2 /HER2 showed 84.4% and 93.9% concordance, respectively. ctDNA temporal heterogeneity analysis revealed 14 patients with fluctuating ERBB2 status and 3 with fluctuating MSI-H status. CONCLUSION ctDNA testing demonstrates high concordance with tDNA and IHC and offers faster turnaround. Given its minimally invasive nature and strong concordance with tissue-based testing, ctDNA is a reliable tool for genomic profiling and longitudinal monitoring in GEC.
Brain-Only Versus GI-Only Synucleinopathy: A Comprehensive Autopsy Study With Both IHC and SAA
Orru, Christina D., Beach, Thomas G., Adler, Charles H., Shill, Holly A., Driver-Dunckley, Erika, Mehta, Shyamal H. , Atri, Alireza, Lorenzini, Ileana , Qiji, Sanaria H., Intorcia, Anthony J., Hughson, Andrew G., Groveman, Bradley R. , King, Samantha, Parveen, Sabiha , Caughey, Byron, Serrano, Geidy E , Orru, Christina Doriana , Beach, Thomas G. , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika , Atri, Alireza , Hughson, Andrew G. , Alam, Parvez , Vascellari, Sarah , Caughey, Byron W. , Serrano, Geidy E.

Mayo Clinic

No container title available | March 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.18.26348355 | PMID 41929295 Get It

ABSTRACT Braak and others have proposed that Lewy body pathology (LBP) in Parkinson’s disease (PD) may arise not only in the brain but alternatively from an initial site in the gastrointestinal (GI) tract with subsequent passage to the central nervous system CNS through the vagus nerve or other routes. We tested this hypothesis by using both immunohistochemistry (IHC) and RT QuIC a form of alpha synuclein seed amplification assay (SAA) to detect alpha synuclein LBP in samples from selected brain regions and 10 GI tract sites taken from autopsies of 50 PD subjects and 128 elderly subjects without parkinsonism or dementia including 34 with IHC identified CNS incidental Lewy body disease (ILBD) and 94 with no Lewy body IHC pathology detected (NLB). A positive SAA or IHC result was restricted to the GI tract in only 2 subjects while LBP by either SAA or IHC was restricted to the brain in 11 subjects. To fairly compare GI-only with brain-only synucleinopathy, however, we would have to do SAA on brain samples from all ILBD and NLB cases in at least 4 critical brain regions: olfactory bulb, medulla, pons, and amygdala. Further SAA of brain regions is estimated, based on the proportional results to date, to potentially identify 21 additional brain-only LBP subjects, for a total of 32, if it were done on all of the NLB subjects. From this brain-only LBP is estimated to be 16 times more common than GI-only LBP. To assess the clinical impact of SAA-positive GI sites we found that the number of positive sites per subject is significantly correlated with UPDRS motor score and SCOPA-AUT GI related scores including those for salivation, straining, constipation, and bowel movement.
Piezo1 Mediates Stretch-Induced Wnt/β-Catenin Signaling and ECM Remodeling in Aging Asthmatic Airway Smooth Muscle
Borkar, Niyati A. , Pfeffer-Kleemann, Daniel , Ngassie, Maunick Lefin Koloko, Thomspon, Michael A, Pabelick, Christina M, Prakash, Y.S., Hamrick, Samantha K. , Ngassie, Maunick Lefin Koloko , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | March 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrcmb/aanag058 | PMID 42083982 Get It

Abstract Asthma in the elderly (AIE) represents a unique challenge, necessitating better understanding of the mechanisms that drive airway hyperreactivity and remodeling (thickened, fibrotic airways). Normal aging is associated with increased lung stiffness, and thus the influence of mechanical forces on bronchial airways (breathing, sighs, CPAP) likely changes, potentially increasing with AIE and resultant remodeling, overall highlighting the need to understand the importance of mechanobiology in aging and AIE. Here, mechanosensitive Piezo (Pz) channels are highly expressed in the lung, including within airway epithelium and smooth muscle (ASM) but their specific roles particularly with aging remain largely unexplored. In this study, we used human ASM cells from young vs. old (≥65 y) non-asthmatics vs asthmatics to test the hypothesis that normal aging blunts Pz expression and functionality at baseline as well as in response to mechanical stretch, whereas asthma, particularly, AIE ASM leads to enhanced Pz expression promoting fibrosis and remodeling. Both Pz1 and Pz2 were expressed in ASM and increased in AIE. Oscillatory mechanical stretch mimicking breathing with superimposed static stretch increased Pz, especially in AIE: effects exacerbated by Pz activator Yoda1 and blunted by Pz inhibitor GsMTx4. Stretch or Yoda1 increased Wnt3a, β-catenin and GSK3β activation particularly in AIE, while ASM proliferation and extracellular matrix production remained preserved or even heightened in elderly ASM. Conversely, Pz1 inhibition by GsMTx4 potently reduced ECM deposition, particularly in AIE cells, highlighting Pz1's pivotal role in modulating ECM deposition. Overall, our findings indicate Pz1 as a mechanosensitive regulator of airway remodeling in AIE.